Daniela Boggiani

450 total citations
15 papers, 279 citations indexed

About

Daniela Boggiani is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniela Boggiani has authored 15 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniela Boggiani's work include Breast Cancer Treatment Studies (5 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). Daniela Boggiani is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). Daniela Boggiani collaborates with scholars based in Italy, France and United States. Daniela Boggiani's co-authors include Andrea Ardizzoni, Antonino Musolino, Beatrice Bortesi, Cecilia Bozzetti, Marcello Tiseo, Gabriella Sammarelli, Marco Bartolotti, Francesco Gelsomino, Maria Michiara and Benedetta Pellegrino and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Daniela Boggiani

15 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniela Boggiani Italy	9	195	123	81	80	59	15	279
Aurélie Maran-Gonzalez France	7	165 0.8×	88 0.7×	54 0.7×	119 1.5×	28 0.5×	16	258
Dominique J P van Uden Netherlands	7	143 0.7×	76 0.6×	41 0.5×	136 1.7×	44 0.7×	15	277
Santino Minichillo Italy	9	160 0.8×	120 1.0×	84 1.0×	137 1.7×	34 0.6×	17	347
Morana Vojnic United States	7	132 0.7×	165 1.3×	129 1.6×	45 0.6×	41 0.7×	24	276
Borgny Ytterhus Norway	11	178 0.9×	53 0.4×	192 2.4×	125 1.6×	57 1.0×	23	370
Juan Antonio Barrera Spain	5	161 0.8×	106 0.9×	151 1.9×	132 1.6×	27 0.5×	7	299
Kammei Rai Japan	8	104 0.5×	138 1.1×	144 1.8×	112 1.4×	20 0.3×	34	333
Julia Ellermann Germany	3	60 0.3×	50 0.4×	119 1.5×	70 0.9×	55 0.9×	3	251
Nadia Tosti Switzerland	10	135 0.7×	66 0.5×	162 2.0×	166 2.1×	42 0.7×	16	328
Svenja Wagener‐Ryczek Germany	10	135 0.7×	111 0.9×	95 1.2×	67 0.8×	28 0.5×	19	243

Countries citing papers authored by Daniela Boggiani

Since Specialization

Citations

This map shows the geographic impact of Daniela Boggiani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Boggiani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Boggiani more than expected).

Fields of papers citing papers by Daniela Boggiani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Boggiani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Boggiani. The network helps show where Daniela Boggiani may publish in the future.

Co-authorship network of co-authors of Daniela Boggiani

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Boggiani. A scholar is included among the top collaborators of Daniela Boggiani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Boggiani. Daniela Boggiani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Pellegrino, Benedetta, Claudia Omarini, Mirco Pistelli, et al.. (2022). Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. The Breast. 65. 145–150. 9 indexed citations

Tommasi, Chiara, Benedetta Pellegrino, Daniela Boggiani, et al.. (2021). Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers. Frontiers in Oncology. 11. 700853–700853. 8 indexed citations

Pellegrino, Benedetta, Alba Llop‐Guevara, Nicoletta Campanini, et al.. (2021). 145P High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis. Annals of Oncology. 32. S423–S424. 1 indexed citations

Musolino, Antonino, Daniela Boggiani, Benedetta Pellegrino, et al.. (2020). Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. Critical Reviews in Oncology/Hematology. 149. 102927–102927. 14 indexed citations

Braud, Filippo de, Jean‐Pascal Machiels, Daniela Boggiani, et al.. (2020). A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. Cancers. 12(6). 1425–1425. 4 indexed citations

Boggiani, Daniela, Maria Michiara, Nadia Naldi, et al.. (2019). Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review. Frontiers in Oncology. 9. 759–759. 22 indexed citations

Musolino, Antonino, Fabio Falcini, Daniela Boggiani, et al.. (2017). Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study. European Journal of Cancer. 88. 10–20. 3 indexed citations

Pellegrino, Benedetta, et al.. (2017). Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.. PubMed. 88(3). 329–333. 16 indexed citations

Musolino, Antonino, Nadia Naldi, Maria Vittoria Dieci, et al.. (2016). Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. The Pharmacogenomics Journal. 16(5). 472–477. 20 indexed citations

10.

Pellegrino, Benedetta, Mariangela Bella, Maria Michiara, et al.. (2016). Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.. PubMed. 87(1). 54–63. 6 indexed citations

11.

Musolino, Antonino, Daniela Boggiani, Anita Rimanti, et al.. (2015). Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers. Cancer Treatment Reviews. 43. 1–7. 13 indexed citations

12.

Musolino, Antonino, Maria Michiara, Daniela Boggiani, et al.. (2015). Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study.. Journal of Clinical Oncology. 33(15_suppl). 594–594. 1 indexed citations

13.

Musolino, Antonino, Maria Michiara, Daniela Boggiani, et al.. (2012). Human Epidermal Growth Factor Receptor 2 Status and Interval Breast Cancer in a Population-Based Cancer Registry Study. Journal of Clinical Oncology. 30(19). 2362–2368. 22 indexed citations

14.

Musolino, Antonino, et al.. (2010). Activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma. Cancer. 117(5). 964–973. 36 indexed citations

15.

Tiseo, Marcello, Francesco Gelsomino, Daniela Boggiani, et al.. (2010). EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 71(2). 241–243. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact